Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Melon

Otolaryngology Hickory, NC Medical Doctor

NPI 1407054760 CMS profile 886931

304 10Th Ave Ne, Hickory, NC 28601

Open in the dashboard

General payments

$13,741

39 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Melon of Hickory, NC is reported in the CMS Open Payments database as having received $13,741 across 39 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,264 17
2024 General $705 7
2023 General $173 4
2022 General $254 6
2021 General $195 2
2020 General $16 1
2019 General $135 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Melon
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to David Melon were reported at $12,264. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year David Melon Otolaryngology median Middle half National median
2019 $135 $194 $82–$512 $163
2020 $16 $118 $42–$280 $114
2021 $195 $167 $63–$444 $132
2022 $254 $216 $84–$545 $149
2023 $173 $235 $93–$588 $160
2024 $705 $280 $111–$699 $164
2025 $12,264 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Inspire Medical Systems, Inc. $12,663 21 payments
  2. Aerin Medical Inc. $515 5 payments
  3. Acclarent, Inc $165 4 payments
  4. Medtronic, Inc. $118 1 payment
  5. MED-EL Corporation $117 1 payment
  6. Stryker Corporation $117 3 payments
  7. Boston Scientific Corporation $21 1 payment
  8. Cook Medical LLC $16 1 payment
  9. Neurent Medical Limited $7 1 payment
  10. Forte Bio-Pharma LLC $3 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $8,788 2 payments
  2. Food and Beverage $2,273 32 payments
  3. Honoraria $2,000 1 payment
  4. Travel and Lodging $681 4 payments
Products named General payments · program years 2019–2025
  1. INSPIRE $12,471 20 payments
  2. VIVAER STYLUS $515 5 payments
  3. RHINAER STYLUS $515 5 payments
  4. Inspire Upper Airway Stimulation System $192 1 payment
  5. TruDi NAV Cable $123 1 payment
  6. PTEYE PARATHYROID DETECTION SYSTEM $118 1 payment
  7. MED-EL Maestro Cochlear Implant System $117 1 payment
  8. VIBRANT Soundbridge Middle Ear Implant and BONEBRIDGE System $117 1 payment
  9. ADHEAR System $117 1 payment
  10. XPRESS ENT DILATION SYSTEM $63 1 payment
  11. Other $135 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,179

Median for Otolaryngology: 297

Drug cost

$17,243

Median for Otolaryngology: $6,314

Branded share of claims

9.3%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ipratropium Bromide Generic 110 $3,498
Synthroid Levothyroxine Sodium Brand 17 $2,005
Fluticasone Propionate Generic 161 $1,867
Montelukast Sodium Generic 173 $1,673
Pilocarpine Hcl Generic 27 $1,296
Fluocinolone Acetonide Oil Generic 18 $1,040
Triamcinolone Acetonide Generic 25 $685
Levothyroxine Sodium Generic 113 $647
Azelastine Hcl Generic 28 $543
Prednisone Generic 85 $540

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 93 billing codes

Paid by Medicare

$173,198

Medicare's payments for the services billed

Medicare patients

586

Average age 74

Services billed

2,618

326 women, 260 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Ischemic heart disease 26%
Diabetes 25%
Depression 24%
Chronic kidney disease 21%
Osteoporosis 16%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

39 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record